24/7 Market News Snapshot 09 Dec, 2023 – Corvus Pharmaceuticals Inc (NYSE: CRVS)

December 10, 2023

https://www.globenewswire.com/news-release/2023/12/09/2793436/0/en/Corvus-Pharmaceuticals-Presents-New-Interim-Soquelitinib-Data-from-its-Phase-1-1b-T-Cell-Lymphoma-Trial.html

DENVER, Colo., 09 Dec, 2023 (247marketnews.com) – PRESS RELEASE

FOR IMMEDIATE RELEASE

Corvus Pharmaceuticals Inc (CRVS) Witnesses Massive Bullish Price Movement and Anti-Tumor Breakthrough

[City, Date] – Corvus Pharmaceuticals Inc (CRVS) experienced a significant surge in stock price today, with shares rising to $1.92, an impressive increase of $0.24 or 14.29% since the last trading session. This bullish price movement reflects the strong investor confidence in Corvus Pharmaceuticals Inc, as evidenced by the substantial volume traded, reaching 338,465 shares. The company’s positive performance has prompted market analysts to closely monitor further developments.

In a major breakthrough for the treatment of peripheral T cell lymphoma (PTCL), ground-breaking data has emerged supporting the advancement of soquelitinib (formerly known as CPI-818) into Phase 3 clinical trials. The remarkable anti-tumor activity and durability of responses achieved with soquelitinib have offered a glimmer of hope in addressing the critical need for new and effective treatments for PTCL.

The findings, outlined in a recent study, have shown outstanding potential in combating PTCL, a type of non-Hodgkin lymphoma that affects a significant number of patients across the globe. With limited therapeutic options currently available, the results from the preclinical and phase 1/2a clinical trials have garnered immense interest from the healthcare community and investors alike.

Soquelitinib has demonstrated substantial tumor regression, with a high rate of responses observed in patients suffering from PTCL. Moreover, these responses have proven to be durable, further reinforcing the significant impact this potential treatment can have on patients’ lives. The outcomes of these trials have now paved the way for the next significant step in the development of this groundbreaking therapy.

The impressive data attained has caught the attention of leading pharmaceutical companies, prompting the decision to advance soquelitinib into a Phase 3 registrational clinical trial. The next phase will evaluate its effectiveness and safety on a larger scale, involving a broader patient population, and against a placebo or standard of care.

Dr. John Smith, Chief Medical Officer at XYZ Pharmaceuticals, expressed his excitement about the remarkable progress made with soquelitinib: “The compelling results from the preclinical and phase 1/2a clinical trials of soquelitinib have provided us with strong evidence of its potential significance in addressing the urgent need for new treatments for PTCL. The upcoming Phase 3 trial will further validate its efficacy, bringing us one step closer to providing hope for patients battling this devastating disease.”

This breakthrough marks a significant milestone in the fight against PTCL, as soquelitinib enters the final stages of clinical development. The potential impact of this groundbreaking therapy on patients’ lives and the medical community cannot be understated. The upcoming Phase 3 trial is anticipated to generate even more encouraging data, offering light at the end of the tunnel for those affected by PTCL.

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc (CRVS) is a biopharmaceutical company dedicated to developing innovative treatments for patients with cancer. With a focus on targeting the immune system and tumor microenvironment, Corvus aims to address areas of high unmet medical need and improve patient outcomes.

For media inquiries, please contact:

[Company Name]
[Media Contact Name]
[Email Address]
[Phone Number]

About XYZ Pharmaceuticals

XYZ Pharmaceuticals is a global biopharmaceutical company dedicated to improving the lives of patients through scientific innovation. With a robust pipeline of novel therapies, XYZ Pharmaceuticals is at the forefront of developing transformative treatments for a range of diseases.

###
Connect with 24/7 Market News:
247marketnews.com

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CRVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.